Apr 28 2022 Relmada Therapeutics to Report First Quarter 2022 Financial Results and Host Conference Call and Webcast on May 5, 2022 View
Apr 04 2022 Relmada Therapeutics to Present Data at the Ketamine & Related Compounds International Hybrid Conference 2022 View
Mar 23 2022 Relmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2021 Financial Results View
Mar 16 2022 Relmada Therapeutics to Report Fourth Quarter and Full-Year 2021 Financial Results and Host Conference Call and Webcast on March 23, 2022 View
Mar 10 2022 Relmada Therapeutics to Participate in Fireside Chats at Two Upcoming Healthcare Events View
Feb 23 2022 Relmada Therapeutics Announces Top-Line Results of Study Evaluating REL-1017 vs Ketamine for Abuse Potential View
Feb 10 2022 Relmada Therapeutics to Participate in the 11th Annual SVB Leerink Global Healthcare Conference View
Dec 22 2021 Relmada Therapeutics Announces Publication of REL-1017 Phase 2 Study Results in The American Journal of Psychiatry View
Dec 14 2021 Relmada Therapeutics Announces Closing of Public Offering and Full Exercise of Over-Allotment Option View
